Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02229968 · ClinicalTrials.gov registry record · Phase 2

Efficacy of Amicar for Children Having Craniofacial Surgery

A Phase 2 study of Craniosynostosis, sponsored by Children's National Research Institute.

Active
Registry status
Phase 2
Development phase
22
Enrollment target
1
Study location

NCT02229968 is a Phase 2 study of Craniosynostosis that is active but no longer recruiting, run by Children's National Research Institute. The registered enrollment target is 22 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02229968, a Phase 2 study of Craniosynostosis, is active but no longer recruiting, sponsored by Children's National Research Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether Amicar (ε-aminocaproic acid) is effective in reducing blood loss in children undergoing craniofacial reconstruction surgery. The investigators hypothesize that Amicar will decrease intraoperative blood loss and decrease the need for perioperative blood product administration in children undergoing craniofacial surgery.

Conditions Studied

Interventions

  • DRUG normal saline
  • DRUG Amicar (ε-aminocaproic acid)

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2014-10
Est. Completion 2027-03
Phase Phase 2

What the Registry Record Tells You About NCT02229968

The ClinicalTrials.gov registry entry for NCT02229968 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's National Research Institute, which has 92 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Craniosynostosis appearing as the primary indexed condition, and to 2 interventions - of which normal saline is the first listed.

NCT02229968 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT02229968 about?

NCT02229968 is a clinical study titled "Efficacy of Amicar for Children Having Craniofacial Surgery". The purpose of this study is to determine whether Amicar (ε-aminocaproic acid) is effective in reducing blood loss in children undergoing craniofacial reconstruction surgery. The investigators hypothesize that Amicar will decrease intraoperative blood loss and decrease the need for perioperative bl...

What is the current status of trial NCT02229968?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2014-10. Estimated completion is 2027-03.

What conditions does trial NCT02229968 study?

This clinical trial studies the following conditions: Craniosynostosis.

What interventions are being tested in trial NCT02229968?

The interventions under investigation include: normal saline (DRUG), Amicar (ε-aminocaproic acid) (DRUG).

Who is sponsoring clinical trial NCT02229968?

This trial is sponsored by Children's National Research Institute, which has 92 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02229968 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Craniosynostosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.